Christos Sotiropoulos1*, Eftichia Sakka2, Georgios Theocharis3 and Konstantinos Thomopoulos4

Inflammatory Bowel Disease is a chronic, relapsing disease that occurs with acute flare ups and remissions. Among the existing therapies, biological agents have revolutionized the management and the natural progress of the disease, but without lacking side effects. Infliximab, a chimeric monoclonal antibody that suppresses the activity of TNF-α, plays a significant role in the therapeutic management of the disease. However, there are some concerns about the safety of Infliximab because it can trigger acute and delayed hypersensitivity reactions. Delayed hypersensitivity reactions are mostly attributed to the development of antibodies to Infliximab. In this report we present three cases of patients with Inflammatory Bowel Disease treated with Infliximab that developed a delayed hypersensitivity reaction after years of regular treatment.

View PDF